文献速递艾滋病与性传播感染

2015-22年巴黎HIV门诊减药抗逆转录病毒策略的采纳与成本影响

Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015-22: experience from an HIV clinic in Paris, France.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该回顾性研究纳入2015至2022年巴黎某大型HIV门诊2170例病毒抑制的成人感染者,评估减药抗逆转录病毒策略(DRS)的采纳率、疗效与成本。8年间48.3%参与者转换为DRS(间歇治疗580例、两药方案442例),2022年54.6%接受DRS;

要点

  • 8年间48.3%病毒抑制者转换为减药策略,2022年54.6%接受DRS。
  • 病毒学失败率:三药11.2%、两药5.3%、间歇治疗1.8%。
  • 间歇治疗年均成本3388欧元,显著低于三药7643欧元。

核心结论

  • 减药抗逆转录病毒方案被应用于超过半数研究人群,间歇方案高效且节约成本。

研究设计与样本

  • 回顾性研究,纳入2015至2022年巴黎某HIV门诊2170例病毒抑制的成人感染者,每日三药或两药方案,每年至少一次临床和病毒载量评估。

主要发现

  • 2170例中基线每日三药占77.5%、两药占22.5%,中位年龄50.6岁、病毒抑制6.0年。
  • 8年间1048例(48.3%)转换为DRS,其中间歇ART 580例、两药方案442例。
  • 病毒学失败率三药为11.2%、两药为5.3%、间歇ART为1.8%。
  • 2022年1184例(54.6%)接受DRS。

临床怎么用

  • 在病毒抑制的HIV成人中可考虑减药策略,间歇方案高效且节约成本,尤其在资源有限环境值得评估推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While current HIV care includes drug-reduced antiretroviral strategies, intermittent therapy, recently recommended in France, could benefit from further evaluation in real-life clinical practice. OBJECTIVES: To evaluate the uptake, efficacy and cost impact of drug-reduced antiretroviral strategies (DRS) in a large HIV clinic in Paris. METHODS: This retrospective study included all virally suppressed adult individuals living with HIV treated at our clinic from 2015 to 2022, on three-drug (3-DR) or two-drug (2-DR) daily regimens, with ≥1 clinical and viral load assessment recorded per year. We defined DRS as either 2-DR or intermittent oral regimen (4 or 5 days weekly). Main outcomes included DRS uptake, factors associated with DRS prescription, virological failure (VF) by ART strategy and costs. FINDINGS: We analysed 2170 individuals (median age: 50.6, viral suppression: 6.0 years) on daily 3-DR (77.5%) and 2-DR (22.5%). Over 8 years, 1048 participants (48.3%) switched to a DRS that consisted of intermittent ART (ART-I) in 580 participants and a 2-DR in 442 participants. The VF rate was 11.2% for 3-DR, 5.3% for 2-DR and 1.8% for intermittent ART. Overall, in 2022, 1184 participants (54.6%) were receiving a DRS. Average yearly cost of HIV care per participant dropped from €15 687 in 2015 to €7437 in 2022, with per-participant costs of €7643 for 3-DR, €8869 for 2-DR and €3388 for ART-I. CONCLUSIONS: Drug-reduced ART regimens were prescribed to over half of the study population. Intermittent regimens, widely used in our setting, are highly effective and cost-saving, and deserve to be evaluated for implementation, particularly in resource-constrained contexts.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sagaon-Teyssier L, Eremin A, Valantin MA, et al. Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015-22: experience from an HIV clinic in Paris, France. J Antimicrob Chemother. 2025. PMID: 40836880. doi:10.1093/jac/dkaf307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。